Five Hypermethylated MicroRNA Genes as Potential Markers of Ovarian Cancer
- Авторы: Braga E.1,2, Loginov V.1,2, Burdennyi A.1, Filippova E.1, Pronina I.1, Kurevlev S.1, Kazubskaya T.3, Kushlinskii D.3, Utkin D.3, Ermilova V.3, Kushlinskii N.3
-
Учреждения:
- Research Institute of Pathology and Pathophysiology
- Research Centre of Medical Genetics
- N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation
- Выпуск: Том 164, № 3 (2018)
- Страницы: 351-355
- Раздел: Oncology
- URL: https://journals.rcsi.science/0007-4888/article/view/239595
- DOI: https://doi.org/10.1007/s10517-018-3988-y
- ID: 239595
Цитировать
Аннотация
MicroRNA and methylation are important epigenetic mechanisms in the pathogenesis of cancer. The role of a group of microRNA hypermethylated genes in the pathogenesis of ovarian cancer was studied and their diagnostic and prognostic potential was evaluated. Studies on a representative sample of 54 ovarian cancer specimens with the use of methyl-specific PCR resulted in detection of five microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) methylated in the majority of tumor specimens in comparison with paired specimens of histologically intact tissue (37-57% vs. 4-9%, p<0.01). Methylation of three genes (MIR-9-1, MIR-9-3, and MIR-130b) was significantly (p≤0.05) associated with the parameters of ovarian cancer progress (clinical stage, differentiation degree, tumor size, and presence of metastases). These findings attest to oncosuppressive role of the studied microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) in the pathogenesis and progress of ovarian cancer and indicated their prognostic potential.
Об авторах
E. Braga
Research Institute of Pathology and Pathophysiology; Research Centre of Medical Genetics
Автор, ответственный за переписку.
Email: eleonora10_45@mail.ru
Россия, Moscow; Moscow
V. Loginov
Research Institute of Pathology and Pathophysiology; Research Centre of Medical Genetics
Email: eleonora10_45@mail.ru
Россия, Moscow; Moscow
A. Burdennyi
Research Institute of Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow
E. Filippova
Research Institute of Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow
I. Pronina
Research Institute of Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow
S. Kurevlev
Research Institute of Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow
T. Kazubskaya
N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow
D. Kushlinskii
N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow
D. Utkin
N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow
V. Ermilova
N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow
N. Kushlinskii
N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow